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Compounds
Ivan Sosthene Mfouo Tynga and Heidi Abrahamse
Abstract
The deregulation of cell growth in milk-producing glands, milk-carrying 
tubes, or connective tissues is known as breast cancer. It originates from genetic 
mutations and has the ability to metastasize. Primary tumor cells repetitively 
divide and lead to inappropriate mechanisms, tumorigenesis, and carcinogenesis, 
characterized by improper cell type, function, lifetime, and self-destruction. The 
tumor-specific activation is considered to be an effective strategy for selective can-
cer destruction, which remains an issue with conventional therapeutic approaches. 
The tumor microenvironment can be regulated and adapted through an interac-
tion between pH, proteins, and other factors. Principally, human breast cancer 
genes, BRCA1 and BRCA2, produce tumor suppressors that prevent changes in 
genetic materials, as well as ensure their stability. Photodynamic therapy is a 
targeted cancer modality that depends on the photochemotherapeutic agent and 
light characteristics used to activate the compound. The possibility of eradicat-
ing breast cancer depends on continuous development of therapeutic approaches 
using third-generation photochemotherapeutic compounds to improve targeting 
this cancer and its stem cells.
Keywords: breast cancer, cell cycle regulation, genetic mutation,  
tumor microenvironment, cancer therapies, new photosensitizers
1. Introduction
Both males and females have breasts, which are composed of adipose (fat) 
tissues, supplied by nerves, blood vessels, lymph nodes and vessels, connec-
tive tissues, and ligaments. The breasts superimpose the pectoral muscles and 
are predominantly pronounced in females after puberty. Breasts consist of 
mammary glands that contain at least a dozen of lobes, further subdivided into 
lobules, and stimulated lobules are able to initiate and produce milk. The lobules 
are specially structured and connected to a system of ductal channels to deliver 
milk to the nipple. The glandular and ductal structures are surrounded by dense 
fat and connective tissues, which determine the size of a breast (Figure 1) [1, 2]. 
This anatomy is completed by a network of connective tissues, ligaments, 
nerves, and both lymph and blood vessels for proper structural and functional 
processing [3].
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Like any other cell cycle, the breast cell cycle endures proper cell proliferation 
and functioning by duplicating cell genetic materials and giving off two daughter 
cells during each cycle. It consists of four distinctive phases and in the first or 
quiescence phase (G0), the cell remains in a resting state, where cell division is 
stationary. The second is known as the intermitotic phase and is further subdi-
vided into a gap 1 phase (a prior-DNA synthesis stage) in which cell size increase 
and control mechanisms ensure readiness for DNA replication (genetic synthesis) 
and post-DNA synthesis (gap 2) to ensure readiness for actual cell division. The 
mitotic phase or sequential cell division consists of prophase, metaphase, ana-
phase, and telophase. The fourth and final is the cytokinesis phase in which the 
cytoplasm of eukaryotic cells is divided into two identical cells [4, 5]. To guar-
antee the integrity of this outcome, a special group of cyclin-dependent kinases 
(CDKs) play crucial roles in regulating cell cycle progression and are also involved 
in other processes including regulation of transcription, mRNA processing, and 
differentiation [6, 7]. When combined with cyclins in dividing cells, stimulated 
CDKs regulate the sequential events of cell cycle and ensure proper cell division 
[6]. Cyclins belong to a family of proteins without catalytic ability, expressed 
at specific subcellular locations, but are able to bind to CDKs and activate the 
regulatory and catalytic activities [8]. The regulation of downstream proteins 
and specific cell cycle checkpoints at different phases of cell cycle is dictated by 
the cyclin-CDK interactions and combinations of those. For instance, during 
the G1 phase, the combination of cyclin D-CDK4 and cyclin E-CDK2 induces 
phosphorylation of Rb protein, subsequent activation of E2F proteins, and further 
expression of E2F reactive genes. These genes encode for cell cycle regulators 
responsible for G1/S transition. Similarly, during G2 phase, the combination of 
cyclin A-CDK2 and cyclin B-CDK1 prompts phosphorylation and activation of 
FoxM1 and recruitment of a histone deacetylase p300/Creb-binding protein that 
further leads to the expression of FoxM1 target genes. These genes encode for cell 
cycle regulators that are essential for the mitosis and effectors of the chromosomal 
segregation (Figure 2) [9].
Figure 1. 
Schematic representation of the breast. Milk passages from the alveoli through the milk ducts to the nipple 
during breast feeding.
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2. Genetic mutation and types of breast cancer
Abnormal expression or change occurring in the activity of cyclin-CDK com-
binations leads to the loss of cell cycle control, where cells no longer follow the 
distinctive progression and go into a malignant formation [6]. Breast cancer is a 
heterogeneous disease characterized by change in morphology, invasive behavior, 
metastatic ability, and hormone receptor expression, leading to malignant cells 
multiplication in breasts with ability to spread to other parts of the body, if the 
condition is not treated [10, 11]. Breast cancer is the most commonly diagnosed 
invasive cancer in women, and second main reason of cancer-related death, after 
lung cancer. Common symptoms include and are not limited to thickness of breast 
tissues, lumps in the armpits, persistent pain through monthly cycle, pigmenta-
tion change or peeling or scaling of the skin of the breast, altered breast size and 
shape, inverted nipples and rash around the nipple area with a likely discharge [11]. 
Mutations in some genes controlling checkpoints like the cell cycle inhibitors, Rb 
and p53 may induce dysregulated cell cycle and so encourage tumor formation [12]. 
These strategic checkpoints prevent cell cycle progression till the verification of 
essential phase processes and nuclear repair have been completed. Other genes like 
BRCA, which is an abbreviation for breast cancer gene, have been found influenc-
ing the development of breast cancer. In fact, there are two types of BRCA genes, 
BRCA 1 and BRCA 2, and they do not cause but prevent breast cancer by repairing 
DNA breaks, which could encourage uncontrolled growth of tumors and cancer. 
Thus, BRCA genes are tumor suppressor genes. However, in some people (around 
1 in 400), these tumor suppressor genes do not function properly, leading to gene 
Figure 2. 
Cyclin-dependent kinase (CDK) combinations control Rb/E2F- and FoxM1-induced transcription. During 
the G1 phase, cyclin D-CDK4 and cyclin E-CDK2 combinations disassemble Rb-E2F dimer and phosphorylate 
Rb, causing the activation of E2F proteins and the expression of E2F-responsive genes. The genes encode for 
cell cycle regulators required for G1/S transition (cyclin E, cyclin A, CDK1, TK, CDC6, and Orc1). During 
the G2 phase, cyclin A-CDK2 and cyclin B-CDK1 combinations phosphorylate and activate FoxM1, causing 
the recruitment of a histone deacetylase p300/CBP that further activates the expression of FoxM1 target 
genes. These genes encode for mitotic regulators (cyclin B) and chromosomal segregation effectors (Cenpf). 
Rb = retinoblastoma protein CDK = cyclin-dependent kinase, TK = thymidine kinase, CDC6 = components of 
the DNA replication machinery, Orc1 = origin recognition complex subunit 1, CBP = CREB binding protein, 
Cenpf = centromere protein factor.
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mutation. When mutated, BRCA genes can no longer carry out their function of 
repairing broken DNA and preventing breast cancer. Due to this genetic malfunc-
tion, mutated BRCA gene carriers are more prone to develop breast cancer even at a 
younger age and can equally pass this mutation down to offspring. This seems to be 
rare with less than 10% of diagnosed women having BRCA mutation. Individuals 
with the BRCA1 mutation have 55–65% chance of developing cancer before age 70, 
compared to a lesser portion, 45%, for individuals with the BRCA2 mutation. The 
BRCA1 mutation is the worse of the two and BRCA1 mutated individuals are more 
likely to develop a triple negative breast cancer, a hormone dependent form, more 
aggressive and lesser curable, with higher risk of developing second cancer after 
successful treatment, known as breast cancer recurrence. However, the majority of 
breast cancer cases can be successfully cured when detected early, even those with a 
BRCA1 or BRCA2 mutation [13].
There are several types of breast cancers, and ductal carcinoma in situ (DCIS) is 
a non-metastatic and non-invasive type that occurs in the ductal cells and this type 
might be highly curable. Lobular carcinoma (LCIS) is another in situ non-metastatic 
and non-invasive type, which occurs in cells of the milk-manufacturing lobules, but 
has the potential to evolve into an invasive type of breast cancer. The most common 
type is certainly the invasive ductal carcinoma that occurs in the ductal cells and 
then invades other breast areas with metastatic abilities. Similarly, the invasive lobu-
lar carcinoma starts in the lobules and has metastatic abilities; however, it is a very 
uncommon type of breast cancer. The breast cyst is a noncancerous (benign) type 
with fluid-filled sac that may be drained. This type is usually diagnosed in females 
who are in their 30s or 40s. Another early and noncancerous solid type is breast 
fibroadenoma, commonly affecting vicenarian and tricenarian women in their 
20s and 30s and is characterized by the presence of a pain-free and mobile lump in 
the breast. Fibrocystic breast is a common noncancerous condition with a breast 
lump that may be altered throughout the menstrual cycle. The breast hyperplasia 
is characterized by the abnormal proliferation of noncancerous cells in ductal areas 
and may increase the risk of developing breast cancer. An atypical breast hyperpla-
sia may develop either in ductal or lobular areas and might significantly increase 
the rsik of breast cancer by four to five times when compared to a healthy woman. 
The intraductal papilloma is a noncancerous wart-like growth within the ducts 
that may cause bloody fluid leakage from the nipple. Another noncancerous condi-
tion is breast adenosis that is caused by lobular expansion and has to be diligently 
diagnosed, as it may resemble breast cancer in some occurrences. Another difficult 
to diagnose type of breast cancer (as it might bear a resemblance to fibroadenoma) is 
phyllodes tumor, a rare and immense breast tumor that may be benign or malignant 
and develop around age 40. Fat necrosis may seem like breast cancer but is a lump 
scar tissue as a result of repairs occurring in the fat tissues of the breast. Commonly 
occurring in nursing mothers, mastitis is an inflammation of the breast as a result of 
infection accompanied by redness, pain, warmth, and swelling. Breast calcification 
refers to the calcium deposits in the breast and has to be diagnosed accordingly, as 
it may suggest something else. More and more seen is the overdevelopment of male 
breasts, known as gynecomastia, and it may affect men of all ages [14, 15].
3. Chemistry, pathophysiology, and staging of breast cancer
The characteristics of the environments where breast cancer develops are similar 
to those of any other cancer. In order to survive, cancer cells must maintain a suit-
able acid-base balance. As a result of extensive carbon dioxide and lactic acid pro-
duction, cancer cells are constantly experiencing acid–base fluxes, which severely 
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affect the pH, especially intracellular pH. To maintain a suitable intracellular pH 
level, specialized pH-dependent transporters regulate the exchange of H+ or HCO3
− 
ions [16]. These specialized proteins are able to induce pH changes by facilitating 
new interactions or eliminating others [17]. Cancer cells need substantial input of 
energy for their ever-increasing metabolic demand. Human tumors tend to grow 
around blood vessels, causing extracellular acidity in tumors and outermost cells 
to become necrotic. The low microenvironmental oxygen tension and pH are the 
hallmarks of cancer [18–20]. Swiftly, tumors become poorly perfused and require 
extra diffusion mechanisms, and carbonic anhydrase plays essential functions in 
controlling extracellular pH and giving cancer cells alternatives to adjust to micro-
environmental acidity and drive disease progression [16].
Although individuals with family history of breast and ovarian cancers have 
higher risk, both myoepithelial and epithelial cells found in the stratified epithelium 
of breast are understood to be able to initiate breast carcinogenesis or stem cells that 
give rise to them [21, 22]. Immune mechanisms aim to identify and destroy cancer 
cells and DNA-damaged cells. Moreover, RAS/MEK/ERK and PI3K/AKT pathways 
control the mechanisms of cell suicidal events. Breast cancer commonly arises due to 
genetic mutations and environmental factors that alter these mechanisms. Exposure 
of epithelial and/or stromal cells to a certain level of estrogen or adipose-derived 
hormones or signaling factors can promote cell proliferation and carcinogenesis in 
breast [23, 24]. Telomerases cease to perform chromosomal shortening roles, exten-
sive cell replication occurs, cancer cells continue to proliferate beyond boundaries 
through blood and lymph systems, and form secondary tumors [25, 26].
The deepness, size, and type determine the stage of breast cancer from non-
invasive to metastatic tumor [27]. Starting in confined localization, tumor initiates 
without evidence in neighboring cells and a well-known instance of stage 0 breast 
cancer is DCIS [28]. The next is the invasive stage and is characterized by two 
categories: stage 1A is a tumor with a diameter lesser than 2 cm and absent in lymph 
nodes, while stage 1B describes a tumor greater than 2 cm in diameter and present 
in lymph nodes [29]. Then, there are two other sub-categories where 2A designates 
tumor localization in axillary lymph nodes with a diameter lesser than 5 cm and 2B 
tumor has a diameter greater than 5 centimeters and is not in axillary lymph nodes 
[30]. The third stage is characterized by three sub-categories: 3A describes tumor 
in 4–9 axillary lymph nodes, while 3B tumor can be inflammatory or not with up to 
9 axillary lymph nodal sites and is able to cause ulcer and various skin alterations 
including red, warm, and swollen breast skin. Stage 3C describes a tumor affecting 
at least 10 axillary lymph nodal sites and area below the clavicle [31]. The final and 
advanced stage 4 defines a metastatic tumor that has spread to other organs like 
lungs, bones, liver, brain, and others [32].
4. Some of the current breast cancer therapies and limitations
Breast feeding women have a lesser risk of developing breast cancer and the 
defensive mechanisms have not yet been identified [33]. Breast cancer treatments 
differ and depend on the stage, mass, site, metastatic ability or not of the condition, 
and the health status of the patient. Currently, the main forms of treatment for 
breast cancer employ surgery, radiation therapy, hormone therapy, and chemother-
apeutic agents [15]. Surgery is the foremost utilized strategy for non-metastasized 
breast cancer and varies according to the affected tissues [34]. Lumpectomy is 
known as a breast-conserving surgery, where a partial mastectomy procedure is 
performed at initial stages of the condition and aims to save the major part of the 
breast by removing the affected breast part, together with limited healthy tissues 
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and surrounding lymph nodes. It is often complemented with other forms of treat-
ment in order to prevent mastectomies [35]. However, some of the adverse effects 
are removal of healthy tissues along with the cancer, soreness, short-term inflam-
mation, altered breast appearance, and sclerosis [36]. When not the first choice, 
mastectomy is often recommended whenever the disease persist after lumpectomy 
was not sufficient. Nevertheless, the loss of breast is usually accompanied with a 
profound sense of loss of a woman’s self-esteem and further depression in most 
women [37]. Radiation therapy utilizes high-energy rays to eradicate cancer cells 
and highly proliferating cells, like those in nails, skin hairs, and others as well. 
Brachytherapy is a faster partial breast irradiation that directs radiation mostly 
to and around the affected cancer area, which is better than to irradiate the entire 
breast [38].
Estrogen and progesterone receptors play important roles in the management of 
breast cancer as they are used to enhance the selectivity of the treatment. Hormone-
dependent treatments using estrogen receptors yield better responses than those 
with progesterone [39]. The anti-estrogen drugs are commonly used for breast 
cancer treatments. Tamoxifen had been one of the foremost of these drugs and 
highly recommended for women with positive estrogen receptor breast carcinoma. 
Tamoxifen prevents estrogen from entering into breast cancer cells and further 
development of the condition [40]. Although its therapeutic efficacy for breast 
cancer has relatively low adverse effects when compared to other anti-estrogen 
counterparts, this anti-estrogen drug tends to compete with estrogen for binding 
to estrogen receptors in breast and other organs including uterus, liver, and bones 
[41]. Both raloxifene and tamoxifen are recognized as selective estrogen receptor 
regulators and able to prevent or stimulate estrogen-like activity in different tissues 
by disturbing the estrogen receptors [42]. Additionally, various side effects are asso-
ciated with the use of anti-estrogen agents, and tamoxifen affects venous throm-
bosis, cataract, endometrial cancer, menstrual disorders, and hot flushes, while 
raloxifen brought about lesser damages in some cases and minor danger of cataract 
and thromboembolism than tamoxifen [43, 44]. Chemotherapy can be used prior 
to surgery or postsurgery depending on the condition of the patient; it refers to the 
usage of medicines to eradicate rapidly proliferating and metastatic cancer cells 
or to minimize their development [45]. The most commonly used chemothera-
peutic medicines are Docetaxel, Paclitaxel, Cisplatin, Carboplatin, Vinorelbine, 
Capecitabine, Liposomal doxorubicin, Cyclophosphamide, and Carboplatin, and 
they are associated with numerous side effects [46, 47].
5. Targeted breast cancer therapy
Sometimes, the success of treatment is hindered by drug resistance, which has 
emerged as a main concern for the fight against cancer. Targeted therapy uses drugs 
to target specific genes or proteins to manage some types of breast cancer from devel-
oping and spreading. The human epidermal growth factor receptor 2 (HER2) is a 
gene involved in the development of breast cancer and Herceptin is a commonly used 
drug to target HER2-positive breast cancer [48]. Gene therapy utilizes virus to deliver 
and replicate new genes into patients’ cells to replace damaged genes. This approach is 
a very selective targeted approach for precise molecular abnormalities associated with 
development of breast cancer, like mutated BRCA1 and p53 genes [49, 50].
Cancer stem cells (CSCs) are potential effectors of self-renewal, proliferation, 
and differentiation and play crucial roles in cancer survival and recurrence [51]. 
The necessity for cancer stem-cell therapy for breast cancer is justified by the rec-
ognition of stem cells in normal as well as in malignant tissues of the breast. CSCs 
7Targeted Breast Cancer Treatment Using New Photochemotherapeutic Compounds
DOI: http://dx.doi.org/10.5772/intechopen.84633
have been identified as the source of molecular complexity of breast carcinoma in 
human. Thus, anti-CSC therapeutic approach would assist with prevention and 
management of various forms of cancer cells, including therapeutically resistant 
breast cancer cells by efficient targeting of breast CSC surface markers such as 
ESAþ, CD44þ, CD24−/low, Lineage- and ALDH1high [52, 53]. Owing to unpredict-
able physico-chemical properties of certain therapeutic agents in physiological 
environments, the exploitation of such targeted approaches, like the anti-CSC 
therapy, rests on the usage of suitable delivery systems. Nanomedicine offers the 
option of using specially designed drug-nanocarriers to integrally deliver thera-
peutic agents into cancer sites and CSCs niches [52]. Additionally, this option offers 
additional advantages including the designing of therapeutic systems directed 
towards pump-mediated drug resistant (ATP-driven) while having limited side 
effects on healthy cells and normal stem cells [52].
6. Photodynamic therapy for breast cancer
Photodynamic therapy (PDT) is a minimally invasive and clinically approved 
procedure for eradicating designated malignant cells with precise light activation of 
a non-toxic photochemotherapeutic agent, known as photosensitizer (PS). PDT is a 
Figure 3. 
Photodynamic cancer therapy actions: (1) administration and uptake of a photosensitizer (PS) and ligand-
conjugated PS (LPS), which accumulate into either tumor cells/surrounding. The lower extracellular pH 
improves PS uptake by tumor cells. Conjugation of PS with specific ligands helps to target the vasculature 
surrounding breast tumor cells. (2) light irradiation at a wavelength matching the absorption properties of PS 
and (3) light activation of PS/LPS and induction of cell death. Immuno-activation stimulates phagocytosis of 
PDT-damaged tumor cells and cell removal. PDT may mediate an immune response causing tumor cell death 
at distant sites.
Breast Cancer Biology
8
sequential procedure involving three main steps: (1) administration of a PS, which 
is internalized into either tumor cells or immediate vasculature; (2) local irradiation 
at a wavelength matching the absorbance peak of the PS; and (3) light activation of 
the PS, which mediates energy transfer cascades, generation of cytotoxic reactive 
oxygen species, and subsequent cell death [54, 55]. PDT is a selective approach and 
capable of using the specific traits of the tumor microenvironment of breast cancer. 
The low pH in tumor microenvironment enhances PS uptake into cells and this 
uptake can be further improved by conjugating PS to endothelial cell (EC)-specific 
ligands and target vasculature surrounding tumor (Figure 3). The effect of PDT 
is derived from three mechanisms: direct cytotoxic effects on tumor cells, indirect 
damage to tumor vasculature, and induction of immune responses [56]. Both 
parenchymal (tumor) and stromal (non-tumor) populations coexist in the tumor 
microenvironment, making it different from those of normal cells. There is a strong 
interrelation between these two populations within the tumor microenvironment 
as the ECs (which are stromal) are essential in providing the required hormones, 
oxygen, and other essential nutrients to both populations, while tumor cells develop 
and maintain the endothelial angiogenesis [57, 58]. PDT dosimetry depends on the 
complexity of the parenchymal cells and should take into consideration the stromal 
cells, so as to only attain complete tumor eradication [57]. Hence, the effective 
use of ligands for targeted PDT for breast cancer by conjugating factor VII (fVII) 
(ligand) with verteporfin or chlorin e6 (PSs) to exclusively prompt cell death mech-
anisms in the breast cancer cell population [59, 60]. Such approaches were efficient 
to target neovasculature and drug-resistant breast tumors, but paved the way for 
the improvement of future targeted PDT complexes [59–61]. The high recurrence 
and poor prognosis of breast cancer are directly related to the overexpression of 
certain receptors in breast cancer cells, such as estradiol receptors, the human epi-
dermal growth factor receptor 2, gonadotropin-releasing hormone receptors, and 
tisular factor VII receptors [62]. They are appropriate sites for receptor-targeting 
approaches and beneficial for development of better PDT agents.
7. New photosensitizer-mediated PDT for breast cancer
The uptake and retention of PS by neoplastic cells is a decisive event in the 
progression and success of PDT. In its ground state, the singlet PS possesses two 
electrons with opposed spins. When irradiated at appropriate quantum energy 
(wavelength), the PS absorbs a photon and one of its electrons is excited into a 
higher energy level, which lasts for a few nanoseconds. The excited and unstable 
PS may lose the excess energy by fluorescing (light emission), internal conversion 
(heat emission), or undergoing intersystem crossing to reach a stable and excited 
triplet state with parallel spins and longer lifespan (microseconds). Due to the 
quantum selection rules, the triplet excited PS can interact and transfer its energy 
to molecular oxygen to form singlet oxygen (type II reaction, more common) or 
undergo electron transfer reactions to form reactive oxygen species (type I reaction) 
before returning to its ground state. The most common PSs are porphyrins, chlo-
rins, bacteriochlorins, and phthalocyanines, they all possess tetrapyrrolic structures 
and many are clinically used. Phenothiazine, squaraine, and boron-dipyrromethene 
are major synthetic dyes, while hypericin, riboflavin, and curcumin are natural 
PSs. More and more PSs are being conjugated to antibodies, peptides, proteins, and 
other ligands for targeted PDT. Nanoparticles are multifunctional materials with 
various medical applications and they are mostly used in PDT to deliver PSs to the 
tumor-targeted sites, and recently to increase light penetration into tissue [63]. 
The increased use of nanoparticles as drug carriers significantly reduces the risk 
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of non-specific accumulation and adverse effects in normal cells, while increases 
neoplastic targeting and therapeutic efficiency. Micelles, dendrimers, liposomes, 
and nanotubes are among the commonly used carrier systems in PDT. They do so by 
utilizing the enhanced permeability and retention effect and the acidic conditions 
created around the tumor microenvironment due to the high metabolic activities, 
developing porous endothelial junction and neovascularization [64, 65].
For the last two decades, extensive effort has been directed to the development 
of new PSs from first to third, and from simple to more complex PS entities for 
enhancing PDT outcomes in neoplastic-bearing animals and patients. Currently, 
third-generation PSs are under development in order to improve the PDT outcomes 
with two main research focuses, namely gene engineering-induced PDT and nano-
medicine in PDT [66]. These PSs are synthesized based on specific cancerous char-
acteristics like the Warburg effects, a recognized phenomenon arising due to the 
fact that cancer cells consume higher levels of glucose than normal cells. So, sugar-
conjugated chlorin (glucose-chlorin) PSs which were synthesized showed improved 
cancer cell selective accumulation, induced immunogenic cell damage, and stronger 
antitumor effects than second-generation PSs. Such sugar-conjugated PSs induce 
very robust antitumor effects by targeting sugar receptors on the surface of cancer 
cells and tumor-associated macrophages in stromal cancer cells [67]. Other third-
generation nanomaterial-mediated PSs like Chlorin E6 have shown strong ROS 
generation through formation of ion complexes. They are able to be encapsulated 
in gold nanoparticles as vesicles to achieve better penetration and are used for both 
diagnosis and treatment of cancer due to their strong absorption properties in the 
near-infrared range of 650–800 nm [68]. The cancer cell specificity and selectivity 
of PDT were inadequate with first- and second-generation PSs. With the develop-
ment of third-generation PSs, PDT has become significantly beneficial for enhanc-
ing tumor targeting, tissue penetration depth, and therapeutic efficacy.
8. Conclusions
Breasts are well-developed organs in females for the production of milk during 
lactation. A special group of CDKs are required for proper breast cell cycle and 
functioning at all times. When the cell cycle is no longer under control, breast 
cancer begins to develop and is characterized by several breast morphological 
alternations, as well as chemical and pathophysiological changes. Various means 
of breast treatments are available and the targeted options seem to provide better 
therapeutic value than conventional therapies. PDT has emerged as an effective and 
potent breast cancer treatment; however, it is highly dependent on the develop-
ment of more effective PSs. Thus, the development of new PSs is encouraged and 
PS complexes containing nanoparticles are one of the most recent developments to 
enhance delivery into tumor sites and treatment efficiency and decrease the adverse 
effects, which characterize the nontargeted therapies.
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as well as for investigating the upregulation of BRCA1 and BRCA2 breast cancer 
tumor suppressor genes in order to prevent changes in genetic materials and so 
their eradication.
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